A critical analysis of neuro-oncology clinical trials.

ABSTRACT:

Background

Limitations in trial design, accrual, and data reporting impact efficient and reliable drug evaluation in cancer clinical trials. These concerns have been recognized in neuro-oncology but have not been comprehensively evaluated. We conducted a semi-automated survey of adult interventional neuro-oncology trials, examining design, interventions, outcomes, and data availability trends.

Methods

Trials were selected programmatically from ClinicalTrials.gov using primary malignant central nervous system tumor classification terms. Regression analyses assessed design and accrual trends; effect size analysis utilized survival rates among trials investigating survival.

Results

Of 3038 reviewed trials, most trials reporting relevant information were nonblinded (92%),

SUBMITTER: Kim Y 

PROVIDER: S-EPMC10484169 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature